Janus Henderson Group PLC Purchases 599,203 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO)

Janus Henderson Group PLC boosted its position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) by 18.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,763,195 shares of the company's stock after purchasing an additional 599,203 shares during the quarter. Janus Henderson Group PLC owned about 11.38% of Lexeo Therapeutics worth $33,997,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently bought and sold shares of LXEO. BNP Paribas Financial Markets raised its position in shares of Lexeo Therapeutics by 184.2% in the third quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company's stock worth $50,000 after buying an additional 3,591 shares in the last quarter. Values First Advisors Inc. purchased a new position in shares of Lexeo Therapeutics during the third quarter worth about $67,000. MetLife Investment Management LLC increased its holdings in shares of Lexeo Therapeutics by 121.5% in the 3rd quarter. MetLife Investment Management LLC now owns 14,223 shares of the company's stock worth $129,000 after buying an additional 7,803 shares during the last quarter. Rhumbline Advisers increased its stake in Lexeo Therapeutics by 37.3% in the second quarter. Rhumbline Advisers now owns 13,357 shares of the company's stock valued at $214,000 after acquiring an additional 3,627 shares during the last quarter. Finally, PDT Partners LLC bought a new position in shares of Lexeo Therapeutics during the 3rd quarter valued at about $241,000. 60.67% of the stock is owned by institutional investors.

Lexeo Therapeutics Trading Up 7.8 %

Shares of Lexeo Therapeutics stock traded up $0.55 on Friday, hitting $7.63. The stock had a trading volume of 221,294 shares, compared to its average volume of 579,118. The stock's 50-day simple moving average is $8.21 and its two-hundred day simple moving average is $11.55. Lexeo Therapeutics, Inc. has a one year low of $5.77 and a one year high of $22.33. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 0.01. The stock has a market cap of $252.32 million and a price-to-earnings ratio of -2.41.

Analyst Ratings Changes

A number of research firms recently weighed in on LXEO. Leerink Partners dropped their target price on Lexeo Therapeutics from $20.00 to $19.00 and set an "outperform" rating for the company in a research report on Wednesday, November 13th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $24.00 price objective on shares of Lexeo Therapeutics in a research note on Tuesday, August 13th. HC Wainwright lifted their target price on shares of Lexeo Therapeutics from $21.00 to $23.00 and gave the stock a "buy" rating in a research report on Thursday, November 14th. Finally, Chardan Capital upped their price target on shares of Lexeo Therapeutics from $23.00 to $25.00 and gave the company a "buy" rating in a research report on Wednesday, November 13th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $23.80.

Insiders Place Their Bets

In other Lexeo Therapeutics news, CEO Richard Nolan Townsend sold 5,000 shares of the company's stock in a transaction that occurred on Thursday, October 10th. The stock was sold at an average price of $8.10, for a total transaction of $40,500.00. Following the completion of the transaction, the chief executive officer now owns 120,695 shares of the company's stock, valued at $977,629.50. This represents a 3.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders have sold a total of 12,500 shares of company stock valued at $113,300 in the last quarter. Insiders own 4.50% of the company's stock.

Lexeo Therapeutics Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.